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Pulmonary Histoplasmosis in a patient with Cough, Dyspnea,
Pulmonary Nodule and Rheumatologic Manifestations: Case Report
and Review
Johnson Britto1*

Abstract
In this case report we describe a case of pulmonary histoplasmosis in a healthy adult female living in
Kentucky. The patient presented with two months history of poly-arthralgia and myalgia, intermittent
dry cough, chest tightness, exertional dyspnea, malaise, fatigue and one week history of skin rash.
She did not respond to broad-spectrum antibiotic therapy and she also had extensive endocrine and
rheumatologic work up that was negative. A diagnosis of histoplasmosis was established based on
radiological findings as well as endobronchial ultrasound-guided transbronchial needle aspiration
cytology (EBUS-TBNA) of mediastinal lymph nodes demonstrating necrotizing granuloma with
fungal stains positive for Histoplasma. Patient showed significant clinical improvement on antifungal
treatment. Since symptoms of histoplasmosis are often similar to the symptoms of community
acquired pneumonia, other lung infections or malignancy, our case highlights the importance of
maintaining a high index of suspicion and appropriate radiological, microbiology, and histologic
evaluation especially in patients who live in or have traveled to areas endemic for histoplasmosis and
are not responding to antibiotic therapy. Early diagnosis coupled with prompt initiation of antifungal
treatment may lead to favorable outcomes.

Introduction
Histoplasmosis has worldwide distribution, occurring most
commonly in North, Central, and South America, as well as parts
of Africa and Asia [1, 2]. Histoplasmosis is a granulomatous
disease caused by a dimorphic fungus Histoplasma capsulatum
(H. capsulatum). There are two varieties of H. capsulatum that
are pathogenic to humans, H. capsulatum var. capsulatum and
H. capsulatum var. duboisii. H. capsulatum var. capsulatum is
endemic in eastern United States and Latin America [3], and H.
capsulatum var. duboisii is prevalent in Africa and South East
Asia [4]. In the United States, H. capsulatum is primarily seen in
Mississippi and Ohio River valleys. H. capsulatum grows best in
soil contaminated with bird or bat droppings [5]. Transmission
occurs via inhalation of H. capsulatum spores from the soil.
Sites commonly associated with exposure to H. capsulatum
include old buildings, caves, bridges, where birds have roosted
[6, 7]. Infection may be acquired from exposure to outdoor
activities such as exploring caves, construction, remodeling,
demolition, bird handling, all of which can cause inhalation of
the pathogen through the contaminated soil [8, 9]. The variation
in clinical course due to histoplasmosis depends on the extent
of the exposure to the organism. Histoplasmosis may remain
asymptomatic in most healthy individuals following low-level
exposure and asymptomatic pulmonary histoplasmosis is the
most common syndrome following infection [10]. Fewer than
five percent of exposed individuals develop symptomatic disease
after a low level exposure to H. capsulatum [11]. Symptomatic
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infection usually causes self-limited pulmonary illnesses,
rheumatologic manifestations such as arthritis or arthralgia
involving the large or small joints, dermatologic manifestations
such as erythema nodosum and/or erythema multiforme or
pericarditis. Exposure to heavy inoculum can cause diffuse
pulmonary involvement [12]. Individuals at the extremes of
age or with underlying immunosuppressive conditions can
develop progressive disseminated disease. Histoplasmosis can
involve every organ system during the course of dissemination
[13]. Here, we describe a case of pulmonary histoplasmosis
in a healthy adult female presenting with cough, dyspnea,
pulmonary nodule and rheumatologic manifestations.

Case Report
A middle aged female, former smoker, outdoor worker with
exposure to pigeons and their excreta, otherwise with no
significant past medical history, presented to her primary
care physician with two months history of poly-arthralgia and
myalgia, intermittent dry cough, chest tightness, exertional
dyspnea, malaise, fatigue and one week history of skin rash
consisting of multiple targetoid appearing erythematous
papules of size 0.5-1.0 cm, on both of her hands as well as her
thighs and lower legs. Photograph of the rash on both of her
lower extremities is shown in (Figure 1).
Vital signs during her initial visit to primary care doctor were
temperature 97.5º F, heart rate 82 beats per minute, respiratory
rate 16 breaths per minute, blood pressure 132/78 mm Hg,
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and oxygen saturation 98% on room air. On physical exam,
she had a skin rash with description as noted above, otherwise
she had no respiratory distress, no lymphadenopathy, no joint
swelling or tenderness. Examination of the respiratory system,
cardiovascular system, abdomen, central nervous system was
noted to be unremarkable.

Fig. 1 Skin rash consisting of multiple scattered targetoid appearing
erythematous papules of size 0.5-1.0 cm on bilateral lower extremities.

Initial diagnostic laboratory work up showed leucocyte count
of 9,100 cells/mm3 (no eosinophilia), hemoglobin 14.3 g/dl,
hematocrit 44.3% and platelet count 295,000/mm3. Serum
electrolytes, renal function, liver function tests, and lipid screen
were normal. Urinalysis was negative for protein or blood.
Rapid Streptococcus group A antigen test and Influenza test for
A & B antigens were negative. Chest X-ray (CXR) showed new
linear opacity best seen on the lateral view in the region of the
lingula with differential of fluid or fat within the major fissure
versus small infiltrate in the lingula (Figure 2).

Fig. 2 Initial Chest X-ray (CXR) PA and Lateral showing linear opacity
best seen on the lateral view in the region of the lingula with differential
of fluid or fat within the major fissure versus small infiltrate in the lingula.

High resolution chest computed tomographic (CT) scan was
obtained revealing a linear density seen on the initial chest x-ray
corresponding to a small amount of fat seen extending into the
right major fissure, otherwise no residual infiltrate was noted.
In the right lower lobe, posteriorly, there was a nonspecific
sub-pleural nodule measuring about 8 mm in size. It was new
since the prior chest computed tomographic (CT) scan obtained
seven years ago. Remaining lungs were clear with no evidence of
interstitial lung disease, ground-glass infiltrate, bronchiectasis,
honeycombing or air trapping. Right para-tracheal node was
present. No other mediastinal, hilar, or axillary nodes were
seen. (Figure 3).
PET/CT skull base to mid-thigh was obtained that showed
minimal level of metabolic activity at the site of the right lung
pulmonary nodule, and hypermetabolic sub-carinal and right
para-tracheal lymph nodes (Figure 4). An infectious process,
including possible fungal disease, or malignancy were suspected.

Fig. 3 Chest computed tomographic (CT) scan showing sub-pleural
nodule measuring about 8 mm in size in the posterior aspect of right lower
lobe.
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normal), Erythrocyte Sedimentation Rate (ESR) was normal.
Additional
laboratory
work
up
including
human
immunodeficiency virus serology, syphilis screen, acute
hepatitis panel, urine Histoplasma antigen, serum (1→3)-β-Dglucan, serum fungal serology by immunodiffusion, fungal
blood cultures, serum interferon gamma release assay, were also
negative.
A bronchoscopy was performed and it did not reveal any
endobronchial lesions. Endobronchial ultrasound (EBUS) scope
was introduced and a systematic survey of the mediastinal
lymph nodes was conducted. This revealed enlarged lymph
nodes in stations 7 and 11R. Endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA) of mediastinal
lymph nodes was performed. The adequacy of the specimens
was confirmed with rapid onsite pathology. Following this,
endobronchial specimens, endobronchial brushing and
bronchoalveolar lavage (BAL) were obtained from right lower
lobe, right and left upper lobes.

Fig. 4 PET/CT skull base to mid-thigh showing hypermetabolic subcarinal and right para-tracheal lymph nodes.

A referral to dermatology was made and a punch biopsy of
the skin rash from her right dorsal thigh was performed.
Hematoxylin & Eosin (H &E) stained section of the specimen
showed histiocytes in the dermis arranged in rings, and
distributed in discrete foci throughout the dermis. Granular
and fibrillary mucinous material was present in the foci of a
histiocytic aggregation. In addition, there was superficial and
deep perivascular lymphocytic infiltrate, with likely diagnosis of
granuloma annulare. She was placed on five week course of a
low dose oral prednisone taper with some improvement noted
in her skin rash and joint symptoms.
During the subsequent weeks, due to non-resolution and
persisting nature of her symptoms, she had several follow up visits
with her primary care physician. She received several rounds of
different oral antibiotics without significant improvement in
her symptoms. In an eﬀort to establish a diagnosis, extensive
laboratory work up including rheumatologic/autoimmune and
endocrine work up was performed which included CPK, aldolase,
lactic acid, complement fixation tests, rheumatoid factor,
antinuclear antibody, anti-neutrophil cytoplasmic antibody
screen (MPO & PR3), SS-A/Ro and SS-B/La, ENA antibodies,
Sm/RNP, dsDNA, CCP antibody, anti-glomerular basement
membrane antibody, monoclonal protein, thyroid function
panel, thyroid peroxidase (TPO), thyroglobulin antibody,
parathyroid hormone (PTH intact), Insulin-Like Growth I (IGF1), adrenocorticotropic hormone (ACTH), serum cortisol, serum
ferritin, iron/UIBC/transferrin saturation, vitamin B1, B6, B12
and Vitamin D (25-Hydroxy) levels and ACE level. All of the
above laboratory work up was unremarkable. C-reactive protein
(CRP) was mildly elevated at 6.44 (<5.0 mg/L is considered

Biopsy of the mediastinal lymph nodes, bronchial brushing &
BAL cytology were negative for malignancy. Stains for acidfast bacilli were negative. Stained section of mediastinal
lymph node showed numerous lymphocytes, histiocytes, many
multinucleated giant cells, forming necrotizing granuloma.
Grocott’s Methenamine Silver (GMS) stain also revealed the
presence of small uniform black yeast forms of approximately
2 to 4 µm in size (Figure 5). Some of these yeast forms showed
narrow-based budding, overall morphology was consistent
with Histoplasma. Gram’s stain of BAL and biopsy specimens
showed rare while blood cells, no organisms. Aerobic, anaerobic,
acid fast bacilli and fungal cultures were negative. BAL viral
respiratory panel was negative.

Fig. 5 Photomicrograph: Grocott’s Methenamine Silver (GMS) stained
section of mediastinal lymph node showing necrotizing granuloma
containing small uniform black yeast forms of approximately 2 to 4 µm
size with narrow based budding consistent with Histoplasma (GMS stain,
60X).

The patient was started on oral itraconazole for twelve weeks.
She tolerated the treatment well and successfully completed
her 12-week course of itraconazole for histoplasmosis with
significant improvement in her symptoms.
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Discussion
In this case report, we have described a case of pulmonary
histoplasmosis in a healthy adult female living in Kentucky
who presented with cough, dyspnea, pulmonary nodule and
rheumatologic manifestations. This review focuses on the
epidemiological, clinical, diagnostic, and therapeutic aspects of
histoplasmosis.
Epidemiology
Histoplasmosis is a systemic mycotic infection caused by
Histoplasma capsulatum [14]. It has two distinct pathogenic
forms H. capsulatum var. capsulatum which is endemic in
eastern United States and Latin America [3], and H. capsulatum
var. duboisii which is prevalent in Africa and South East Asia [4].
Histoplasmosis is among the most common endemic mycosis in
the United States with the largest burden of disease occurring
in mid-western states around the Ohio and upper Mississippi
River Valleys [13]. In the United States, an estimated 60%
to 90% of people who live in areas surrounding the Ohio and
Mississippi River valleys (where Histoplasma is common in the
environment) have been exposed to the fungus at some point
during their lifetime [15]. State-specific annual incidence rates
in the mid-west range from 0 to 4.3 cases/100,000 population
[16]. Our case is a good example of pulmonary histoplasmosis in
an immunocompetent individual living around the Ohio River
Valley which is endemic for Histoplasmosis.
Mycology
Histoplasma capsulatum is a dimorphic fungus. The organism
exists in the mold (mycelial) form in the soil and switches to
the yeast form at normal human body temperatures. It finds
a natural habitat in soil with high nitrogen content such as
areas contaminated by bird or bat excrements. Birds do not
transmit the disease; however, bird excretions contaminate the
soil, thereby enriching the growth medium for the mycelium.
Contaminated soil can be potentially infective for years [17].
Pathogenesis
During outdoor activities, H. capsulatum enters the human
host by inhalation of fungal conidia or mycelia fragment.
Once inhaled these fungal elements convert to the yeast form
and replicate within the macrophages, and then spread to the
regional lymph nodes, and throughout the reticuloendothelial
system via parasitized macrophages [18]. Macrophages initially
are able to ingest but not kill the fungi [19, 20]. The infected
macrophages induce inflammatory response and recruit more
macrophages, lymphocytes and plasma cells to destroy the
organism and arrest infection. These coalesce together to
form granulomas consisting of giant cells with central caseous
necrosis, which further undergoes fibrosis and calcification [21].
Even with the development of cell-mediated immunity, patients
can have remaining foci of viable H. capsulatum in various
organs, similar to tuberculosis. These organisms are held in
check by the immune response but are not completely killed,
and thus, reactivation of infection years later is possible [13].
Clinical Manifestations
Clinical findings of histoplasmosis are varied, and the disease
should be considered in the following clinical presentations,
particularly in the appropriate epidemiologic setting:
Pneumonia with mediastinal or hilar lymphadenopathy,
mediastinal or hilar masses suggestive of malignancy or

tuberculosis, pulmonary nodule suggestive of malignancy,
cavitary lung disease suggestive of tuberculosis, pericarditis with
mediastinal lymphadenopathy, pulmonary manifestations with
arthritis or arthralgia plus erythema nodosum, and suspected
sarcoidosis [22].
In most healthy individuals, the most common outcome after
low-level exposure is asymptomatic pulmonary histoplasmosis
[10].
Asymptomatic cases are usually identiﬁed based
upon incidental chest imaging findings such as abnormal
radiographs or computed tomographic (CT) scans showing
enlarged mediastinal or hilar lymphadenopathy or pulmonary
nodules. Less than five percent of exposed individuals develop
symptomatic disease after a low-level exposure to H. capsulatum
[11]. Symptomatic pulmonary histoplasmosis, as noted in our
case report, presents as a subacute pulmonary infection weeks
to months following exposure. Symptoms are usually mild, and
may be accompanied by rheumatologic and/or dermatologic
manifestations or pericarditis in approximately 5% of patients
[13]. Myalgia and arthralgia are common symptoms during
acute infection and appear to be more common in women
[23]. The arthritis is poly-articular and usually symmetric and
involves large or small joints [23]. Joint symptoms usually
resolve spontaneously over several weeks and respond to
nonsteroidal anti-inﬂammatory agents. About fifty percent of
the patients with joint symptoms develop skin lesions. Erythema
nodosum and erythema multiforme are the most common skin
manifestations [24, 25]. They occur most frequently in women
and are thought to be associated with a hypersensitivity response
to the antigens of H. capsulatum [24-26]. Our patient presented
with cough, dyspnea and pulmonary nodule accompanied with
rheumatologic manifestations. Patients who live in endemic
area and present with above clinical features, histoplasmosis
should be strongly considered in the differential diagnosis, and
appropriate diagnostic work up should be performed.
Patients who inhale a large inoculum can develop a severe and
potentially fatal acute diffuse pulmonary infection [10, 27-30].
The onset of illness is abrupt, symptomatic infection can occur
within a week or two [31-33], presenting with fever, chills,
malaise, dyspnea, cough, and chest pain. Chest radiographs
show diffuse reticulo-nodular or miliary pulmonary inﬁltrates.
Disease can progress to respiratory failure or progressive
extrapulmonary dissemination [28, 34-35]. Acute respiratory
distress syndrome can occur within a few days [28-29].
Mediastinal granuloma or granulomatous mediastinitis is a
rare complication of pulmonary histoplasmosis. Mediastinal
lymphadenopathy is common in acute histoplasmosis. However,
instead of enlargement of a few nodes that eventually recede and
ultimately calcify as the host handles the infection, mediastinal
granuloma is characterized by enlarging, encapsulated, caseous
mediastinal lymph nodes which can remain enlarged for months
to even years. Yeast forms of H. capsulatum can sometimes be
seen in the midst of necrotic material that is obtained by needle
aspiration or tissue biopsy [13].
Many patients are asymptomatic, and the nodes are discovered
on a chest radiograph or computed tomographic (CT) scan of
the chest. Radiographs show enlarged hilar, sub-carinal, or
para-tracheal lymph nodes. However, others may experience
variety of symptoms including chest pain, cough, hemoptysis,
and dyspnea due to encroachment of this mass of nodes around
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mediastinal structures such as esophagus, pulmonary vessels
and superior vena cava [10, 36-39]. Rarely, the nodes may
drain spontaneously into the adjacent soft tissues of neck or
airways causing broncho-esophageal or trachea-esophageal
fistula or even the pericardium [10, 37, 40-41]. Chest imaging
findings in our patient showed mediastinal lymphadenopathy
but no characteristic findings of granulomatous mediastinitis
mentioned above were noted.
The development of disease associated with the initial
dissemination of H. capsulatum is dependent on the host.
Patients who are immunosuppressed and are unable to develop
effective cell-mediated immunity against the organism are likely
to manifest symptomatic disease during the period of acute
dissemination. Progressive, clinically evident dissemination
occurs primarily in patients with underlying immunosuppressive
disorders. This includes patients with AIDS, hematologic
malignancies, organ transplant recipients, or those who are on
medications such as corticosteroids [8, 42-46].
Differential Diagnosis
Differential diagnosis of acute pulmonary histoplasmosis
includes acute pulmonary blastomycosis, coccidioidomycosis,
and atypical community-acquired pneumonias, such as those
due to Mycoplasma, Legionella, and Chlamydia. Our patient’s
initial clinical presentation was thought to be due to bacterial
community acquired pneumonia, however our patient failed
to respond to multiple courses of different oral antibiotic
therapy. Hilar or mediastinal lymphadenopathy is common
with histoplasmosis and can be seen with blastomycosis but
would be extremely uncommon with community-acquired
pneumonia caused by Mycoplasma, Legionella and Chlamydia.
Other possibilities include conditions in which parasitized
macrophages are seen, such as leishmaniasis and Penicillium
marneffei infections [47]. The parasites in leishmaniasis lack
the clear halo seen in H. capsulatum and tend to aggregate at
the periphery of the macrophage (marquee sign). Leishmania
donovani (LD) bodies can be distinguished by a nucleus and
bar-shaped kinetoplast within each amastigote and it is negative
for Periodic acid–Schiff (PAS) stain [47]. The Penicillium
marneffei yeast forms replicate by binary division and have a
septate appearance, whereas H. capsulatum divides by narrowbased budding [47]. In the case of histoplasmosis, as noted in
our case report, numerous small 2–4 µm in diameter yeast‑like
microorganisms may be seen within macrophage, multinucleate
giant cells, or within fibrous tissue [48]. Patients who have hilar
lymphadenopathy, arthralgia, and erythema nodosum can be
mistakenly given the diagnosis of sarcoidosis [49, 50]. Also, the
early clinical manifestations of disseminated histoplasmosis
are nonspecific, often leading to diagnostic difficulty and
misdiagnosis as tuberculosis, lymphoma or metastatic
malignancy [51]. Thus, in the appropriate epidemiologic setting,
testing for histoplasmosis should be included for patients who
are under evaluation for these aforementioned conditions.
Diagnosis
Health care providers must be aware of the clinical syndromes
and a careful history of possible exposure to H. capsulatum,
epidemiologic clues, namely activities of daily living, travel
and occupations that expose the patient to sites contaminated
with bat or bird droppings are crucial to arriving at the correct
diagnosis. Also, clinicians must be familiar with the uses and
limitations of the diagnostic tests for fungal diseases.

The clinical picture, chest radiographic findings and
histopathology using stains for fungi, cultures, antigen detection,
and serologic tests for Histoplasma-specific antibodies can all
help make the diagnosis of pulmonary histoplasmosis [52].
Detection of polysaccharide antigen by enzyme immunoassay
(EIA) in either the urine, blood, or bronchoalveolar lavage ﬂuid
is useful in clinically ill patients in need of a quick diagnosis.
Most studies have been performed using a commercial test that
is currently available in the United States. In these studies, an H.
capsulatum galactomannan can be detected in 60 to 83 percent
of patients with acute pulmonary histoplasmosis [52, 53]. The
highest sensitivity is obtained by testing both urine and serum
[54]. Our patient had a negative urine Histoplasma antigen test.
False-positive reactions for Histoplasma antigen in urine are
common among patients who have other endemic mycoses such
as blastomycosis, penicilliosis, and paracoccidioidomycosis.
In one study, 8 of 9 patients with paracoccidioidomycosis, 12
of 19 with blastomycosis, and 17 of 18 with penicilliosis had
urine antigen tests that were positive for Histoplasma antigen
[55]. In North America, there is little concern about this lack of
speciﬁcity, except for those patients who have blastomycosis,
because only the areas of endemicity of histoplasmosis and
blastomycosis overlap [56].
Although not an antigen test, detection of (1→3)-β-D-glucan
(BG) in serum has been shown to be a useful adjunct for
diagnosis of invasive fungal infections, especially candidiasis,
aspergillosis, pneumocystosis, and histoplasmosis [57-59]. The
sensitivity of the test was 87% in histoplasmosis cases and it
had a specificity of 68% with controls. Histoplasmosis should
be considered as a possible cause for a positive BG test, but
such results may be found with many other conditions that are
clinically similar to this fungal disease [60]. Our patient had a
negative BG test.
Serologic tests for antibodies provide the basis for diagnosis
in patients with mild infections, but require at least a month
to appear after the initial exposure. Also, serologic testing may
not be reliable in patients without a compatible clinical picture
or epidemiologic risk factors. The standard assays are the
complement ﬁxation (CF) test that uses two separate antigens,
yeast and mycelial (or histoplasmin), and the immunodiffusion
(ID) assay. Less than 1 percent of residents in endemic areas
are seropositive by the immunodiffusion test and less than
five percent have positive complement fixation assays [61].
Diagnosis is based on a fourfold rise in CF antibody titer; a
single titer of 1:32 is suggestive but not diagnostic. CF antibodies
persist for years after infection; thus, the presence of a single
low CF titer means little other than that the patient was exposed
to H. capsulatum at some time [13]. The CF test appears to be
less speciﬁc than the ID assay; False-positive CF tests occur in
patients with lymphoma, tuberculosis, sarcoidosis, and other
fungal infections, all of which may present as a mediastinal mass
[13, 62-63]. Tissue biopsy is always required in these instances.
Antibody assays may be falsely negative in immunosuppressed
patients. Antibodies can remain positive for several years and
thus may not indicate disease activity [61]. For those patients
who have mediastinal lymphadenopathy, antibody assays
may or may not be positive and cannot be relied upon to
make a deﬁnitive diagnosis. Our patient had a negative serum
Histoplasma antibody by immunodiffusion test.
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The role of polymerase chain reaction (PCR) for diagnosis of
histoplasmosis is uncertain. Several laboratories are working
on developing PCR assays that might help with a more rapid
identiﬁcation of H. capsulatum [64-66]. In one study, PCR was
less sensitive and was positive in only 8% of urine specimens
from patients with histoplasmosis [67]. In another study,
PCR was negative in one third of tissues in which yeast was
seen by histopathology [68]. Currently there are no validated,
and commercially available PCR methods for diagnosis of
histoplasmosis.

histoplasmosis, no treatment is recommended for patients with
asymptomatic mediastinal granuloma as self-resolution may
occur. The recommendation for symptomatic patients is medical
management alone with 6–12 weeks of oral itraconazole [72].

Fungal cultures can be sent from infective material such as
blood, bone marrow or sputum, and they should be observed
for 6–8 weeks before they may be considered negative. They
are useful in patients with chronic pulmonary histoplasmosis
and submission of multiple sputum or bronchoalveolar lavage
cultures produces a positive yield in the majority of cases [69].
The sensitivity of respiratory cultures is much lower in localized
disease or acute disease [70]. Samples of tissue or body ﬂuids
sent to the laboratory for culture are plated onto Sabouraud’s
dextrose agar (SDA) and incubated at 25°C to allow for growth
of the mycelial phase of H. capsulatum. After several weeks,
and sometimes as long as 6 weeks, growth of a white to light
tan mold occurs. Two types of conidia are produced on the
hyphae. The macroconidia, or tuberculate conidia, are 8 to
15 m in diameter and have distinctive projections on their
surface; the microconidia are small (2 to 4 m) and smooth
walled. Identiﬁcation of the tuberculate macroconidia allows
a presumptive diagnosis of histoplasmosis. A deﬁnitive test
to verify that the mold is H. capsulatum should always be
performed. There is a commercially available chemiluminescent
DNA probe which can be used for definitive identification of H.
capsulatum [71].

For mild-to-moderate acute pulmonary histoplasmosis,
treatment is usually unnecessary. Oral itraconazole (200 mg 3
times daily for 3 days and then 200 mg once or twice daily for
6–12 weeks) is recommended for patients who continue to have
symptoms for >1 month [72].

Morphologic findings in biopsy specimens include granulomas,
lymphohistiocytic aggregates, and diffuse mononuclear cell
infiltrates. Histopathologic examination of lung or mediastinal
lymph node tissue using special stains may show yeastphase organisms of Histoplasma, measuring 2 to 4 micron in
diameter, with narrow based budding (as noted in Figure 5 of
our case report). Cultures are usually negative. Other organisms
can mimic the appearance of H. capsulatum in tissues such as
Candida glabrata, Cryptococcus neoformans, Pneumocystis
jirovecii and Leishmania, but radiological and clinical picture
will generally separate histoplasmosis from the others [13].
Treatment
Most infections caused by H. capsulatum are self-limited
and require no therapy. However, patients who are exposed
to a large inoculum of Histoplasma and those who are
immunocompromised usually require antifungal therapy [22]
Amphotericin B, Itraconazole, voriconazole, posaconazole,
isavuconazole and fluconazole, all have in vitro activity against
H. capsulatum. Itraconazole is generally preferred for mild to
moderate histoplasmosis, and amphotericin B has a role in the
treatment of moderately severe and severe infections [72].
The Infectious Diseases Society of America (IDSA) has
published clinical practice guidelines that are based upon
open-label studies, case reports, and expert opinion [72].
According to a 2007 update by the Infectious Disease Society
of America clinical practice guidelines for the management of

For moderately severe to severe acute pulmonary histoplasmosis,
lipid formulation of amphotericin B (3.0–5.0 mg/kg daily
intravenously for 1–2 weeks) followed by oral itraconazole (200
mg 3 times daily for 3 days and then 200 mg twice daily, for a
total of 12 weeks) is recommended [72].

Treatment
for
asymptomatic
pulmonary
nodules
(histoplasmomas) or mediastinal adenopathy is usually
not indicated [51]. In the presence of persistent symptoms,
accompanied by positive antigen tests, CF titers of 1:32 or
higher, histopathology showing yeast resembling H. capsulatum
or positive cultures, oral itraconazole treatment may be
appropriate if no symptomatic improvement occurs after 1
month of observation [12]. Our patient had persisting symptoms
for 2 months and histopathology of mediastinal lymph node
showed necrotizing granuloma and Grocott’s Methenamine
Silver (GMS) stain also revealed the presence of yeast forms
with narrow-based budding consistent with Histoplasma. She
was treated with oral itraconazole for 12 weeks with significant
improvement in her symptoms.
Arthritis or arthralgia with erythema nodosum occurs in 5%–
10% of cases as a systemic inﬂammatory response to acute
pulmonary histoplasmosis [24, 27]. These manifestations do
not represent infection, and they respond to nonsteroidal antiinﬂammatory agents without antifungal therapy. In some cases,
the manifestations are moderately severe, requiring treatment
with corticosteroids [27]. If corticosteroids are used, concurrent
itraconazole treatment is recommended to reduce the risk of
progressive infection.
Prevention
There is no vaccine against histoplasmosis. In areas where the
fungus is common, it may not be possible to prevent infection.
Pets, particularly cats & dogs, can get histoplasmosis, but it is
not contagious between animals and people [73]. Birds don’t
appear to be able to get histoplasmosis. It may be difficult to
avoid inhaling the spores of Histoplasma in the areas where it
is endemic. Avoiding areas with bird and bat droppings may
provide some protection. Wearing a respirator face mask can
provide protection for workers in contaminated areas.

Conclusion
In conclusion, we report a case of pulmonary histoplasmosis in
a patient presenting with cough, dyspnea, pulmonary nodule
and rheumatologic manifestations. Our case highlights the fact
that histoplasmosis can present with variable manifestations
in immunocompetent individuals living in endemic region
for histoplasmosis. Our patient presented with nonspecific
symptoms with a vast differential diagnosis prompting a thorough
work up and eventually leading to endobronchial ultrasound-
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guided transbronchial needle aspiration cytology (EBUSTBNA) of mediastinal lymph nodes demonstrating necrotizing
granuloma with fungal stains positive for Histoplasma. Patient
was treated with antifungal therapy and showed significant
clinical improvement. This fungal disease accounts for a good
number of cases of nonspecific flulike illness especially in
endemic areas, but its inconsistent clinical manifestations
often hinder a straightforward diagnosis. Thus, a high degree
of suspicion and epidemiological reasoning on the part of the
health care providers is required to consider histoplasmosis in
differential diagnosis. In this context, our case report illustrates
the following points: 1) cough, dyspnea and pulmonary nodule
(accompanied with rheumatologic and/or skin manifestations)
in patients especially living in the endemic areas should always
alert the clinician of the possibility of histoplasmosis. 2) Starting
oral antifungal therapy (Itraconazole) may lead to favorable
outcomes in patients presenting with pulmonary nodule and/
or mediastinal lymphadenopathy with persisting symptoms
for more than one month and histopathology showing yeast
resembling H. capsulatum.
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